95 related articles for article (PubMed ID: 16824658)
1. Gender differences in prolactin elevation induced by olanzapine in Japanese drug-naïve schizophrenic patients.
Sawamura K; Suzuki Y; Fukui N; Sugai T; Someya T
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Dec; 30(8):1511-4. PubMed ID: 16824658
[TBL] [Abstract][Full Text] [Related]
2. Gender-specific prolactin response to antipsychotic treatments with risperidone and olanzapine and its relationship to drug concentrations in patients with acutely exacerbated schizophrenia.
Yasui-Furukori N; Saito M; Nakagami T; Sugawara N; Sato Y; Tsuchimine S; Furukori H; Kaneko S
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Apr; 34(3):537-40. PubMed ID: 20170699
[TBL] [Abstract][Full Text] [Related]
3. Serum prolactin levels and the acute-phase efficacy in drug-naïve schizophrenia treated with ziprasidone and olanzapine (translated version).
Wu XL; Wang JH; Hu SH; Tao J
East Asian Arch Psychiatry; 2012 Mar; 22(1):7-11. PubMed ID: 22447799
[TBL] [Abstract][Full Text] [Related]
4. Gender differences in onset of illness, treatment response, course, and biologic indexes in first-episode schizophrenic patients.
Szymanski S; Lieberman JA; Alvir JM; Mayerhoff D; Loebel A; Geisler S; Chakos M; Koreen A; Jody D; Kane J
Am J Psychiatry; 1995 May; 152(5):698-703. PubMed ID: 7726309
[TBL] [Abstract][Full Text] [Related]
5. The effects of olanzapine and fluphenazine on plasma cortisol, prolactin and muscle rigidity in schizophrenic patients: a double blind study.
Jakovljevic M; Pivac N; Mihaljevic-Peles A; Mustapic M; Relja M; Ljubicic D; Marcinko D; Muck-Seler D
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Mar; 31(2):399-402. PubMed ID: 17126974
[TBL] [Abstract][Full Text] [Related]
6. Impact of a switch from typical to atypical antipsychotic drugs on quality of life and gonadal hormones in male patients with schizophrenia.
Kaneda Y; Kawamura I; Fujii A; Ohmori T
Neuro Endocrinol Lett; 2004; 25(1-2):135-40. PubMed ID: 15159697
[TBL] [Abstract][Full Text] [Related]
7. Switching to risperidone after unsuccessful treatment of olanzapine in the first-episode schizophrenia: an open trial.
Takahashi H; Yoshida K; Ishigooka J; Higuchi H
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Aug; 30(6):1067-72. PubMed ID: 16759777
[TBL] [Abstract][Full Text] [Related]
8. The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia.
David SR; Taylor CC; Kinon BJ; Breier A
Clin Ther; 2000 Sep; 22(9):1085-96. PubMed ID: 11048906
[TBL] [Abstract][Full Text] [Related]
9. The effects of antipsychotic drug treatment on prolactin concentrations in elderly patients.
Kinon BJ; Stauffer VL; McGuire HC; Kaiser CJ; Dickson RA; Kennedy JS
J Am Med Dir Assoc; 2003; 4(4):189-94. PubMed ID: 12837139
[TBL] [Abstract][Full Text] [Related]
10. Dose-dependent effects of olanzapine on QT intervals and plasma prolactin levels in Japanese patients with stable schizophrenia.
Suzuki Y; Ono S; Sugai T; Fukui N; Watanabe J; Tsuneyama N; Sawamura K; Someya T
Hum Psychopharmacol; 2011 Aug; 26(6):440-3. PubMed ID: 21823168
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and tolerability of olanzapine in the treatment of adolescents with schizophrenia and related psychotic disorders: results from a large, prospective, open-label study.
Dittmann RW; Meyer E; Freisleder FJ; Remschmidt H; Mehler-Wex C; Junghanss J; Hagenah U; Schulte-Markwort M; Poustka F; Schmidt MH; Schulz E; Mästele A; Wehmeier PM
J Child Adolesc Psychopharmacol; 2008 Feb; 18(1):54-69. PubMed ID: 18294089
[TBL] [Abstract][Full Text] [Related]
12. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study.
McQuade RD; Stock E; Marcus R; Jody D; Gharbia NA; Vanveggel S; Archibald D; Carson WH
J Clin Psychiatry; 2004; 65 Suppl 18():47-56. PubMed ID: 15600384
[TBL] [Abstract][Full Text] [Related]
13. Differences in the effect of second-generation antipsychotics on prolactinaemia: six weeks open-label trial in female in-patients.
Svestka J; Synek O; Tomanová J; Rodáková I; Cejpková A
Neuro Endocrinol Lett; 2007 Dec; 28(6):881-8. PubMed ID: 18063941
[TBL] [Abstract][Full Text] [Related]
14. Correlation of antipsychotic and prolactin concentrations in children and adolescents acutely treated with haloperidol, clozapine, or olanzapine.
Alfaro CL; Wudarsky M; Nicolson R; Gochman P; Sporn A; Lenane M; Rapoport JL
J Child Adolesc Psychopharmacol; 2002; 12(2):83-91. PubMed ID: 12188977
[TBL] [Abstract][Full Text] [Related]
15. Olanzapine plasma concentration, average daily dose, and interaction with co-medication in schizophrenic patients.
Bergemann N; Frick A; Parzer P; Kopitz J
Pharmacopsychiatry; 2004 Mar; 37(2):63-8. PubMed ID: 15048613
[TBL] [Abstract][Full Text] [Related]
16. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial.
Tollefson GD; Beasley CM; Tran PV; Street JS; Krueger JA; Tamura RN; Graffeo KA; Thieme ME
Am J Psychiatry; 1997 Apr; 154(4):457-65. PubMed ID: 9090331
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of olanzapine, an atypical antipsychotic, in patients with schizophrenia: results of an open-label multicenter study in Japan.
Ishigooka J; Murasaki M; Miura S;
Psychiatry Clin Neurosci; 2001 Aug; 55(4):353-63. PubMed ID: 11442886
[TBL] [Abstract][Full Text] [Related]
18. Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia.
Ascher-Svanum H; Stensland M; Zhao Z; Kinon BJ
BMC Psychiatry; 2005 Jan; 5():3. PubMed ID: 15649317
[TBL] [Abstract][Full Text] [Related]
19. Olanzapine plasma concentrations after treatment with 10, 20, and 40 mg/d in patients with schizophrenia: an analysis of correlations with efficacy, weight gain, and prolactin concentration.
Citrome L; Stauffer VL; Chen L; Kinon BJ; Kurtz DL; Jacobson JG; Bergstrom RF
J Clin Psychopharmacol; 2009 Jun; 29(3):278-83. PubMed ID: 19440083
[TBL] [Abstract][Full Text] [Related]
20. A simple switching strategy for inadequately treated patients with schizophrenia to olanzapine: changes in psychopathology and subjective well-being.
Kluge M; Wehmeier PM; Dittmann RW; Langer F; Czekalla J; Lehmann M; Kessler FH; Beyenburg S; Naber D
Pharmacopsychiatry; 2005 Jan; 38(1):6-12. PubMed ID: 15706459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
